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In allergic alterations of human skin the majority of
infiltrated leukocytes express CD44v3, but no other
CD44 variant isoform. Vessel endothelium, too, is
brightly stained with a CD44v3-specific antibody.
Being concerned about therapeutic intervention, it
became of importance to define whether expression
of CD44v3 on the endothelial cells or on the leukocytes
or on both is of functional importance. As expression
of CD44v3 in the mouse on activated endothelium
and on subpopulations of activated CD4F cells, B cells
and monocytes was similar to the expression in the
human, we answered the question in a mouse delayed-
type hypersensitivity model. The effect of anti-CD44v3
was compared with the effect of anti-CD44s and
anti-CD44v10, both known to suppress delayed-type
hypersensitivity reactions. Anti-CD44v3 mitigated the
delayed-type hypersensitivity reaction in dinitro-
fluorobenzene sensitized and challenged mice com-
parable with anti-CD44s and anti-CD44v10. The
seemingly similar effects of CD44 isoform-specific
antibodies, however, resulted from a distinct modula-
CD44 comprises a set of transmembrane glycoproteins,whose members differ by glycosylation (Lesley et al,1993) and by insertion of up to 10 variant exonsbetween exon 5 and exon 6 of the CD44 standardisoform (CD44s) (Screaton et al, 1993). Considering
functions of CD44 on hematopoietic cells, CD44s has been
described originally as a lymphocyte homing receptor (Jalkanen
et al, 1986). Meanwhile, it is known also to be involved in
lymphocyte maturation (Kincade et al, 1993; Siczkowski et al, 1993;
Sugimoto et al, 1994; Toyama-Sorimachi et al, 1995), traffic (Camp
et al, 1993; Wu et al, 1993; Mikecz et al, 1995; DeGrendele et al,
1997, 1993), and activation (Funaro et al, 1994; Shimizu et al,
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tion of response. Anti-CD44s mainly suppressed T cell
activation and interleukin-2 as well as interferon-g
expression. Anti-CD44v10 inhibited the activation of
monocytes in the draining lymph nodes and in the
infiltrate, which led to a strong reduction in the
proinflammatory cytokines tumor necrosis factor-a
and interleukin-12 and in edema formation. Anti-
CD44v3 had only a weak effect on cytokine expression
by isolated subpopulations of leukocytes, but sup-
pressed cytokine production by helper T cells when
cocultured with antigen-presenting cells, i.e., blocked
an interaction between antigen-presenting cells and
helper T cells. The dominating effect of anti-CD44v3,
however, relied on a blockade of leukocyte extra-
vasation. As leukocytes transferred into dinitrofluoro-
benzene sensitized, anti-CD44v3-treated and lethally
irradiated mice did not infiltrate the sensitized skin,
anti-CD44v3 most likely prevented leukocyte extra-
vasation by blocking CD44v3 on endothelial cells. Key
words: CD44 isoforms/cytokines/delayed-type hypersensi-
tivity/leukocyte migration. J Invest Dermatol 113:11–21,
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1989; Pierres et al, 1992; Galandrini et al, 1993; Naujokas et al,
1993). Knowledge of functional activity of CD44 variant isoforms
is still scarce: CD44v3 seems to be involved in hematopoiesis,
particularly myelopoiesis (Bennett et al, 1995; Jackson et al, 1995).
Lymphocyte activation has been shown to be accompanied by
upregulation of CD44v6 (Arch et al, 1992; Koopman et al, 1993;
Galluzzo et al, 1995; Levesque and Haynes, 1996). CD44v10 is
involved in the activation of virgin B cells, in a process which
requires an interaction between conventional antigen-presenting
cells (APC) and the virgin B cell (Ro¨sel et al, 1998). Considering
the relevance of CD44v expression in pathology it has been
demonstrated in animal models that anti-CD44s and anti-CD44v6
interfere with collagen-induced arthritis (Verdrengh et al, 1995;
Brennan et al, 1997). Anti-CD44v7, but neither anti-CD44s nor
anti-CD44v6 nor anti-CD44v10, cures a lethal TH1 (T helper
cell)-mediated experimental colitis (Wittig et al, 1998). Delayed-
type hypersensitivity (DTH) reactions can be mitigated by anti-
CD44s, anti-CD44v6, and anti-CD44v10 (Camp et al, 1993; Ro¨sel
et al, 1997; Weiss et al, 1997).
The mode by which CD44 communicates with the intracellular
signal transduction pathway has not yet been unraveled, but there
is evidence that the tyrosine kinase p56lck may play a central part
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(Taher et al, 1996). Cross-linking of CD44 has also been described
to initiate intracellular Ca21 mobilization (Galluzzo et al, 1995).
Furthermore, CD44 has been assumed to stimulate production of
the cytokines interleukin (IL)-1, IL-2, monocyte colony-stimulating
factor and of the insulin-like growth factor (Webb et al, 1990;
Gruber et al, 1992; Noble et al, 1993). Alternatively, CD44 could
anchor cytokines and chemokines via proteoglycan side chains and
by this means influence lymphocyte attraction and motility (Tanaka
et al, 1993; Bennett et al, 1995; Weber et al, 1996). Finally, CD44
has been described to function as the ligand of a costimulatory
molecule (Guo et al, 1996).
As mentioned above, TH1-mediated DTH reaction can be
mitigated by application of CD44v10 (Ro¨sel et al, 1997). As
leukocyte infiltrates as well as endothelial cells in patients with
allergic skin reactions express CD44v3, the question arose whether
anti-CD44v3 also would interfere with the DTH reaction. Further-
more, it became of interest (i) whether both CD44v isoforms
function via the same mechanism, and (ii) whether the pathologic
over-reactivity could be most efficiently blocked, e.g., by an
antibody, at the level of the leukocytes or the endothelial cells. We
approached the question by an in vivo model of a 2,4-dinitro-1-
fluorobenzene (DNFB) induced DTH reaction. Anti-CD44v3, like
anti-CD44s and anti-CD44v10, efficiently mitigated the inflam-
matory response. CD44s, CD44v3, and CD44v10, however, display
distinct modes of action. CD44s is involved directly in T and B
cell activation as well as in leukocyte traffic. CD44v10 supports
monocyte activation. CD44v3 takes part in a TH–monocyte inter-
action, but mainly is required for the extravasation of activated
leukocytes.
MATERIALS AND METHODS
Blood samples Heparinized blood (10 ml) was collected from 24 healthy
donors (10 female, 14 male; mean age, 32 6 8 y; range, 24–54 y), from
10 patients with viral and bacterial infections of the skin (four female, six
male; mean age, 48 6 17 y; range, 20–77 y) and from 15 patients (eight
female, seven male; mean age, 50 6 14 y; range, 25–74 y) with an allergic
reaction of the skin (e.g., urticaria, contact eczema, atopic dermatitis). The
diagnosis had been verified for all patients by conventional clinical criteria.
peripheral blood leukocytes (PBL) from patients were collected before
therapeutic treatment. PBL were separated by Ficoll Hypaque centrifuga-
tion. Where indicated, PBL were stimulated for 48 h with phytohemag-
glutinin A (PHA) (2 µg per ml) in RPMI 1640, supplemented with
antibiotics, L-glutamine, 10–5 M 2-mercaptoethanol, 10–3 M HEPES
buffer, 10% fetal bovine serum.
Mice and treatment BALB/C mice were obtained from WIGA
(Sulzfeld, Germany). They were kept under specific pathogen-free condi-
tions and were fed sterilized tap food and water ad libitum. Animals were
used for experiments at the age of 8 wk. Contact allergy was induced by
painting 20 µl of 0.5% DNFB in 4:1 acetone/olive oil on the rear footpads
of mice for a successive 2 d. Four days later, mice were challenged by
painting 10 µl of 0.2% DNFB to each side of both ears (Tang et al, 1996).
In most experiments mice received concomitantly with the first painting
and 4 d thereafter either rat immunoglobulin (Ig)G, anti-CD44s, anti-
CD44v3, or anti-CD44v10 (200 µg per 100 µl phosphate-buffered saline),
intravenously. Where indicated, antibody was applied only at the first
contact with DNFB or at the time of challenge. Ear thickness was measured
near the root and the tip of the ears 48 h after challenge.
Monoclonal antibodies The following monoclonal antibodies were
used: Anti-CD44s (IM-7, rIgG2b), anti-CD44v10 (K926, rIgG2a) (34),
anti-CD44v3 (PTS33, rIgG2b),1 anti-interferon (IFN)-γ (R4–6A2, anti-
rIgG), anti-µ (131.12, rIgG2b), anti-CD4 (YTA3.2.1, rIgG2b), anti-CD8
(YTS169.4.1, rIgG2b), anti-Mac-1 (YBM6.1.1, rIgG2a), anti-IL-2R (7D4,
rIgG2b), and anti-ICAM-1 (YN1/1.7.4, rIgG2b) (ECACC). The 25–32
hybridoma (anti-hCD44s, mIgG2b) was obtained from the ECACC. The
human CD44 variant specific antibodies vFF327 (anti-CD44v3, mIgG1),
vFF8 (anti-CD44v5, mIgG1), vFF7 and vFF18 (anti-CD44v6, mIgG1),
vFF9 (anti-CD44v7, mIgG1), vFF17 (anti-CD44v7-v8, mIgG2b), and
1Engel P, Zo¨ller M: Functional activity of CD44v3 in hematopoietic
progenitor maturation. In preparation.
vFF16 (anti-CD44v10, mIgG1) were kindly provided by Bender & Co.
GMBH (Vienna, Austria), and have been described in detail elsewhere
(Heider et al, 1993). Culture supernatants were purified by passage over
Protein G-Sepharose and monoclonal antibodies were used in vitro at a
concentration of 10 µg per ml. Anti-CD40, anti-CD40L, anti-CD80, anti-
CD86, anti-CD28, anti-CTLA4 and pairs of anti-IL-2, anti-IL-12, anti-
IFN-γ and anti-tumor necrosis factor (TNF)-α were obtained commercially
(Pharmingen Hamburg, Germany). For flow cytometry, 3–5 3 105 cells
were stained according to routine procedures using either fluorescein
isothiocyanate-labeled and phycoerythrin (PE)-labeled isotype-specific sec-
ondary antibodies or biotinylated first antibodies and streptavidin–PE for
detection. When assaying cytokine producing cells, lymphocytes were
fixed and permeabilized in advance. As far as they had been stimulated
in vitro, 5 µM monensin was added to the culture medium during the last
8 h of culture. Fluorescence was determined with an EPICS XL (Coulter,
Hialeah, FL).
Lymphocyte separation and in vitro stimulation Leukocytes were
isolated after sensitization or after sensitization and challenge with DNFB
from draining lymph node cells, the infiltrate of the ear and the peritoneal
cavity (PEC). Single cell suspensions of infiltrating leukocytes were obtained
by incubating the ear, inner side down, for three times 30 min at 37°C in
0.5% trypsin, collecting the cells in the supernatant. Lymph nodes were
meshed through fine gauze. The cell suspensions were washed twice with
phosphate-buffered saline. Where indicated, lymphocyte populations were
depleted of adherent cells (monocytes) by 2 3 1 h plastic adherence. B
cells were enriched by panning on anti-µ coated plates (Wysocki and Sato,
1978) collecting the adherent fraction. Lymph node cell preparations were
enriched for CD41 and CD81 cells by panning on anti-µ-coated plates
and by depletion of plastic adherent cells collecting in both instances the
nonadherent fraction. These nonadherent cell populations were then
incubated with either anti-CD4 (rIgG2b) or anti-CD8 (rIgG2b) and after
washing were plated on anti-rat IgG-coated plates, from where the adherent
population was collected. According to analysis by flow cytometry the
individual populations were enriched by 90%–95%. For flow cytometry of
cytokine expressing subpopulations of leukocytes, cells were cultured for
48 h in medium containing DNP-OVA (dinitrophenyl-ovalbumin) (100 µg
per ml) and 10 µg per ml of either rat IgG or anti-CD44v3 or anti-
CD44v10. The culture medium contained in addition 10% supernatant of
concanavalin A (Con A) activated rat spleen cells as a source of T cell
growth factor after Con A has been blocked by α-methylmannoside. In
experiments where cytokine expression by CD41 cells was determined
after coculture with B cells, the B cells had been irradiated (3000 R);
when CD41 cells were cocultured with monocytes care was taken to
collect only the nonadherent cells. For the determination of cytokine
secretion, cells were cultured in flat bottom 96 well plates, which had
been coated with anti-interleukins. Cytokine secretion was determined
after 24 h of culture in the medium described above.
Enzyme-linked immunosorbent assay and enzyme-linked
immunosorbent spot assay Plates were coated with the CD44v3
peptide EDFTDYPSFSG (10 µg per ml). After washing and blocking with
bovine serum albumin, 50 µl of biotinylated anti-CD44v3 (2 µg per
ml) was added. Plates were washed again, alkaline phosphatase-labeled
streptavidin and finally the substrate were added. The optical density of
the enzyme reaction was measured after 20 min at 450 nm. For the
enzyme-linked immunosorbent spot assay plates were coated with anti-IL-
2, anti-IL-12, anti-IFN-γ, or anti-TNF-α in bicarbonate buffer, pH 8.9.
Plates were washed and blocked with bovine serum albumin (100 µg per
ml). Cells were added to the coated plates and were incubated for 24 h at
37°C in RPMI 1640, supplemented with antibiotics, L-glutamine, 10–5 M
2-mercaptoethanol, 10–3 M HEPES buffer, 10% fetal bovine serum and
100 µg DNP-OVA per ml. Thereafter, cells were lysed, plates were washed
three times and 50 µl biotinylated antibody was added. Plates were
incubated overnight at 4°C. After four washings, the enzyme (streptavidin–
alkaline phosphatase) was added in phosphate-buffered saline, gelatin, and
Tween20. Plates were incubated for 90 min at 37°C, they were washed
five times before adding the substrate in 1% agar. Spots were counted after
incubation at 37°C for 4 h.
Normal human tissue and biopsies of patients with alteration of
the skin Normal human skin was derived from surgical specimens
(discarded tissue). Tissues from patients with allergic alterations of the skin
were derived from biopsies undertaken as routine diagnostic procedure,
i.e., the tissue has been left after routine immunohistochemical staining
and was not part of any study. All biopsies were taken at first diagnosis
and before systemic treatment. Biopsies were obtained from patients
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Figure 1. Expression of CD44 variant
isoforms in allergic skin reactions. (A) PBL
of 15 healthy donors, of 15 patients with allergic
and of 10 patients with infectious alterations of
the skin were stained with anti-CD44s, anti-
CD44v3, anti-CD44v6, anti-CD44v7, and anti-
CD44v10. The mean percentage (1SD) of
freshly harvested PBL and of PBL stimulated for
48 h with PHA (2 µg per ml) are shown.
Significance of differences are indicated by
asterisks (*p , 0.1, **p , 0.01, ***p , 0.001).
(B) Freshly harvested (a, b) and activated (2 µg
per ml PHA, 48 h) (c, d) PBL of a healthy donor
(a, c) and a patient with disseminated contact
eczema (b, d) were stained with anti-CD44s
and anti-CD44v3. Single parameter overlays are
shown. White area: negative control. Black area:
anti-CD44v3-stained cells. Gray area: anti-
CD44s stained cells. (C) A skin biopsy of a
patient with a contact eczema has been stained
with anti-CD44v3 (a) and of a patient with a
maculopapular cutaneous drug eruption has been
stained with anti-CD44v10 (b). The majority of
the few infiltrated cells were stained by anti-
CD44v3, some of the infiltrated cells were
stained by anti-CD44v10. Vessel endothelia were
clearly stained by both antibodies.
with urticaria (three), atopic dermatitis (two), contact eczema (five), and
maculopapular cutaneous drug eruption (one). The mean age of the patients
was 43 6 19 y (range, 21–74 y). Biopsies were from six female and five
male patients. Diagnosis of all patients was verified by clinical and
pathologic criteria.
Immunohistology Human biopsies and sensitized skin of mice were
excised and either fixed in formaldehyde for paraffin sections or snap
frozen in liquid nitrogen for immunohistology (Cattoretti et al, 1988).
Sections of about 0.4 cm2 were cut in 4–6 µm thick sections, mounted
on gelatin coated slides and air-dried overnight. They were fixed in acetone
for 10 min at –20°C and stored at –80°C. Fixed and dried sections were
incubated for 1 h at room temperature with the first antibody. Slides were
washed intensively and incubated at room temperature for 30 min with a
second, biotinylated anti-rat IgG antibody. After washing, sections were
incubated with a horseradish-peroxidase-conjugated streptavidin complex.
The substrate for the enzyme was either 3-amino-9-ethylcarbazole or
Texas Red (Sigma, St. Louis, MI). The peroxidase reaction resulted in an
intense red precipitate. The sections were faintly counterstained with
Mayer’s hematoxylin, air-dried and mounted. For negative controls staining
of each sample was performed without applying the primary antibody or
by using an antibody of irrelevant specificity. No staining was observed in
these samples.
Statistics Significance of differences were calculated by the two-tailed
Student’s t test.
RESULTS
Expression of CD44 variant isoforms in PBL and infiltrates
of patients with allergic skin reactions Freshly harvested as
well as PHA-stimulated PBL from healthy donors and patients
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Figure 2. Expression of CD44v3 on murine
leukocytes. (A) The newly generated anti-CD44v3
antibody PTS33 specifically binds to CD44v3 pep-
tide-coated plates. (B) Staining of in vitro stimulated
lymph node cells (DNP-OVA plus T cell growth
factor) with anti-CD44s and anti-CD44v3. Single
parameter overlays are shown. White area: negative
control. Gray area: anti-CD44v3-stained cells. Black
area: anti-CD44s-stained cells. (C) Double fluores-
cence analysis of Con A activated lymph node cells
(anti-CD4, anti-CD8), lipopolysaccharide (LPS)
activated spleen cells (SC) (anti-sIgM) and LPS
activated PEC (anti-CD11b) with anti-CD44v3.
Activated lymph node cells, SC and PEC have been
stained with anti-CD4, anti-CD8, anti-µ and anti-
CD11b (first antibody) and counterstained with
fluorescein isothiocyanate-labeled anti-rat IgG
(fluorescence 1, X-axis) as well as with biotinylated
anti-CD44v3 (first antibody) and with streptavidin–
PE for detection (fluorescence 2, Y-axis). The
negative control has been incubated with rat IgG,
fluorescein isothiocyanate-labeled anti-rat IgG and
streptavidin–PE. The population of large cells
(lymph node cells, SC) and of large and more
granulated cells (PEC) has been gated.
with allergic skin reactions were stained with CD44 isoform
specific antibodies and were analyzed by flow cytometry (Fig 1A).
Expression of CD44s and CD44v6 was elevated in freshly harvested
PBL of patients with allergic skin reactions as compared with PBL
of healthy controls. After in vitro stimulation, expression of CD44s
and CD44v6 was augmented on PBL of healthy donors and the
difference to PBL of patients with allergic skin reactions had
disappeared. Instead, a small, but significantly increased population
of PBL from patients expressed CD44v3. As demonstrated in
Fig 1(B), a low percentage of CD44v31 cells was detected even
in activated PBL of a healthy donor. Yet, a significantly higher
percentage of CD44v31 cells was detected in the PBL of a patient
with a contact eczema. As compared with the intensity of CD44s
expression, CD44v3 expression was more than a decade lower.
Distinct to freshly harvested PBL, the intensity of expression of
CD44s on activated PBL was comparable in healthy donors and in
patients with allergic skin reactions.
It has been described before that leukocytes infiltrating the skin
contain few, but strongly CD44v31 cells. Infiltrates of patients
with allergic and other alterations of the skin rarely stain with anti-
CD44v10 and do not stain with anti-CD44v6 and anti-CD44v7
(Seiter et al, 1998). Notably, endothelial cells in unaltered (data
not shown) and allergen-reactive skin are CD44v31 as well as
CD44v101 (Fig 1C).
The rather selective expression of CD44v3 on PBL, dermal
infiltrates and activated endothelial cells of patients with allergic
skin reactions prompted us to evaluate in a mouse model of a
DNFB-induced DTH reaction the possible functions of this CD44
variant isoform. Since anti-CD44s as well as anti-CD44v10 are
known to interfere with TH1 DTH reactions, evaluation of these
isoforms has been included in the study.
Expression of CD44v3 and CD44v10 on subpopulations of
activated murine leukocytes The newly generated CD44v3-
specific antibody PTS33 has been derived from a fusion of Ag8
cells with rat spleen cells after immunization with a synthetic
peptide covering the amino acids EDFTDYPSFSG of the CD44v3
exon product. As shown in Fig 2(A), the antibody specifically
binds to CD44v3 peptide coated plates. It also recognizes Ag8 cells
transfected with CD44v3, but not nontransfected Ag8 cells (data
not shown).
In a pilot experiment it was tested whether murine lymphocytes
display a comparable pattern of CD44v3 expression as observed on
human PBL. Expression of CD44v10 on resting and activated
murine leukocytes has already been described, i.e., CD44v10 is
not expressed on resting murine lymph node cells, but 10%–15%
of activated lymph node cells express CD44v10. CD44v10 was
predominantly expressed on monocytes and B cells (Ro¨sel et al,
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Figure 3. Expression of CD44v3 and CD44v10
in dermal infiltrates of DNFB sensitized mice.
Mice were sensitized with DNFB, the skin was
excised 48 h after sensitization and was shock frozen.
Sections of 5 µm were stained with anti-CD44v3
and anti-CD44v10. Basal layers of the epidermis
were stained by anti-CD44v3 (a). Part of the infilt-
rated leukocytes were stained by anti-CD44v3 (b)
and, distinct to the human skin, also by anti-
CD44v10 (c). Notably, endothelial cells (arrowhead),
too, expressed CD44v3 and CD44v10. Scale
bar: 2.5 µm.
1997, 1998). The CD44v3-specific antibody also did not stain
nonactivated lymph node cells (data not shown), but stained 20%–
30% of blasts, although the intensity of expression was weak as
compared with CD44s (Fig 2B, Table I). Staining of leukocyte
subpopulations (Table II) and double fluorescence analysis (Fig 2C)
revealed that CD44v3 is expressed on a part of CD41 cells, B cells
and monocytes, but hardly on CD81 cells. A similar distribution
has been observed on activated human PBL.2
Considering expression of CD44 variant isoforms in epidermis
and dermis of the mouse (Fig 3), expression of CD44v10 is
restricted to the basal layers of the epidermis (Ro¨sel et al, 1997).
CD44v3, too, is expressed in the epidermis. Both, CD44v3 and
CD44v10 are moderately expressed on vessel endothelia and
infiltrating leukocytes. As there is no distinct marker for Langerhans
cells in the mouse, CD44 variant isoform expression on these cells
could not be defined. In the human, however, some but not all
Langerhans cells express CD44v3 (Seiter et al, 1998).
CD44v3 and CD44v10 specific antibodies influence a TH1-
mediated DTH reaction A DTH reaction was induced by
painting with DNFB, which after challenge of the ears provides a
strong inflammatory stimulus with erythema, edema, and massive
leukocyte infiltration. The peak reaction is observed after 2 d, at
which time-point the draining lymph nodes and the infiltrate were
analyzed. All three CD44-specific antibodies mitigated the DTH
reaction. Considering edema formation, anti-CD44v10 exerted the
strongest effect, but the differences in the efficiency to anti-CD44v3
and anti-CD44s were minor (Table III). The number of infiltrated
cells, however, was more strongly reduced in anti-CD44v3 and
anti-CD44v10 than in anti-CD44s-treated mice (Fig 4). Anti-
CD44 antibodies obviously also influenced expansion of lympho-
cytes in the draining lymph node. Interestingly, a reduction in the
number of lymphocytes in the draining lymph node was only seen
with anti-CD44s and anti-CD44v10. Instead, mice receiving anti-
CD44v3 showed a significantly increased number of cells in the
draining lymph node.
The uniform influence of the anti-CD44 antibodies on leukocyte
infiltrates in combination with the differential expression pattern
of CD44 isoforms on leukocyte subsets and the opposing influence
on the number of cells in the draining lymph nodes indicated that
CD44v3 and CD44v10 may exert distinct modes of action despite
the seemingly similar end result. To obtain hints as to the possible
mechanisms, we next evaluated the composition of leukocytes and
expression of costimulatory molecules in draining lymph node cells
and the infiltrate.
2Wittig B, Seiter S, Schmidt DS, Zuber M, Neurath M, Zo¨ller M:
Selective upregulation of CD44 variant isoforms on peripheral blood
leukocytes of patients with chronic inflammatory bowel disease. Lab Invest,
in press.
Table I. Expression of CD44v3 and CD44v10 on activated
murine lymphocytes
Intensity of staining
Antibody % Stained cellsab (peak)b
Negative control 2.3 6 0.2 0.1 6 0.03
Anti-CD44s 96.5 6 7.4 242.8 6 23.1
Anti-CD44v3 19.4 6 2.2 5.9 6 0.71
Anti-CD44v10 12.3 6 1.9 8.2 6 1.14
a Lymph node cells were stimulated in vitro by Con A (7.5 µg per ml) for 48 h.
b The mean 6 SD of five experiments are shown.
Table II. Expression of CD44v3 and CD44v10 on
subpopulations of activated leukocytes
% CD44 variant isoform expressing cellsb
Leukocyte subseta CD44v3 CD44v10
CD41 29.6 6 3.6 4.8 6 0.9
CD81 6.1 6 1.0 7.2 6 1.2
CD11b1 28.8 6 2.6 27.3 6 2.8
sIgM1 22.6 6 2.7 11.9 6 2.1
a Draining lymph node cells and PEC (for CD11b1 cells) were collected 5 d after
sensitization with DNFB and were separated by panning according to the description
in Materials and Methods. The purity of the separated populations was in the range
of 90%– 95%.
b The mean 6 SD of five experiments are shown.
Table III. Edema after DNFB sensitization and challenge:
influence of anti-CD44
Ears: mean thicknessb (mm) (p values)
Antibodya Root Tip
Control IgG 3.11 6 0.32 0.25 6 0.027
Anti-CD44s 1.18 6 0.09 (,0.001) 0.12 6 0.016 (,0.001)
Anti-CD44v3 1.16 6 0.11 (,0.001) 0.12 6 0.014 (,0.001)
Anti-CD44v10 1.00 6 0.14 (,0.001) 0.10 6 0.011 (,0.001)
aMice were sensitized and challenged with DNFB and received concomitantly
with the first sensitization and 3 d thereafter 200 µg antibody, i.v.
bEdema formation of the ears was determined by measuring the thickness towards
the root and the tip of the ears at 48 h after challenge, mean 6 SD of 10 mice/
group are shown.
Leukocyte subset composition in the draining lymph node
and in the infiltrate in DTH reactions under the influence
of anti-CD44v3 and anti-CD44v10 The distribution of CD41
cells, CD81 cells, and monocytes in the draining lymph nodes of
DNFB sensitized and challenged mice showed only minor differ-
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Figure 4. Influence of anti-CD44v3 and anti-
CD44v10 on leukocyte expansion and infiltra-
tion in DNFB-induced DTH reactions. Mice
were sensitized and challenged with DNFB and
received concomitantly with the first sensitization
and 3 d thereafter an intravenous injection of 200 µg
antibody. Mice were killed 2 d after the challenge,
the draining lymph nodes were excised and leuko-
cytes infiltrating the ear were isolated as described
in Materials and Methods. The mean (1SD) number
of leukocytes in the draining lymph node (A) and
the infiltrate (B) are shown. Values were derived
from 10 mice per group. Significance of differences
are indicated by asterisks (*p , 0.1, **p , 0.01,
***p , 0.001).
Figure 5. Distribution of leukocyte sub-
populations in the draining lymph node and
the infiltrate of DNFB sensitized and chal-
lenged mice. DTH was induced as described above
and leukocytes from the draining lymph node and
the infiltrate were isolated 48 h after challenge.
Cells were stained with anti-CD4, anti-CD8, and
anti-CD11b. The mean (1SD) percentage of stained
leukocytes in the draining lymph node (A) and the
infiltrate (B) are shown. Values were derived from
10 mice per group. Significance of differences are
indicated by asterisks (*p , 0.1, **p , 0.01,
***p , 0.001).
ences in dependence on the application of anti-CD44 antibodies
(Fig 5). This was different in the infiltrate, where the number of
CD41 and CD81 cells was strongly reduced in anti-CD44v3-
treated mice. In anti-CD44s and anti-CD44v10-treated mice only
the relative percentage of monocytes was significantly reduced.
None of the three antibodies exerted a major effect on the
expression of T cell costimulatory molecules. Yet, expression of
the ligands for costimulatory molecules on APC, like CD40, CD80
and CD86, was slightly but consistently reduced in anti-CD44v3-
treated mice (data not shown).
In view of the distinct influence of anti-CD44s, anti-CD44v3,
and anti-CD44v10 on leukocytes infiltrating the injured organ, it
became tempting to speculate that anti-CD44s and anti-CD44v10
may interfere with leukocyte activation and migration/extra-
vasation, whereas anti-CD44v3 seemed to influence particularly
leukocyte migration/extravasation. The following experiments
were particularly concerned with an elucidation of the latter
phenomenon.
Influence of CD44 isoform-specific antibodies on leukocyte
activation and leukocyte migration To differentiate between
an influence of anti-CD44s, anti-CD44v3, and anti-CD44v10
on leukocyte activation versus migration and extravasation, the
antibodies were applied either during the sensitization or during
the elicitation period and leukocyte expansion. Edema formation
and leukocyte infiltration into the injured organ were monitored
(Table IV). When the antibodies were given only during the
sensitization period, expansion of lymphocytes in the draining
lymph node was still strongly impaired in anti-CD44s-treated and
anti-CD44v10-treated mice. The number of draining lymph node
cells recovered from anti-CD44v3-treated mice was increased,
although to a minor degree. Edema formation was reduced, but
the reduction was less pronounced, particularly in anti-CD44s-
treated animals. The number of infiltrated cells also had been
reduced, the reduction being less pronounced in anti-CD44v10-
treated mice. When the antibodies were applied only at the time
of challenge, expansion of lymphocytes in the draining lymph node
was hardly affected. In anti-CD44v3-treated and anti-CD44v10-
treated mice the reduction in edema formation was as strong as in
mice receiving antibody treatment throughout the test period; only
anti-CD44s exerted a weaker effect. Considering the number of
infiltrated cells, only anti-CD44v10 was less effective when given
only during the elucidation phase; the reduction by anti-CD44v3
and anti-CD44s was as strong as when given repeatedly.
These data confirmed our working hypothesis that anti-CD44s
and anti-CD44v10 influence both lymphocyte expansion and
leukocyte migration/extravasation, anti-CD44s exerting a stronger
effect on lymphocyte expansion, anti-CD44v10 interfering more
efficiently with leukocyte recruitment/extravasation. Instead, anti-
CD44v3 strongly inhibits leukocyte migration/extravasation, only.
Antibody blockade of CD44v3 on endothelial cells hampers
leukocyte extravasation We have mentioned above that endo-
thelial cells are stained by anti-CD44v3 and anti-CD44v10. To
evaluate whether expression of CD44v3 and CD44v10 on endo-
thelial cells actively contributes to leukocyte extravasation, mice
were sensitized with DNFB, lethally irradiated and treated with
anti-CD44v3 or anti-CD44v10. Mice were rested for 48 h to
allow for excretion/degradation of the bulk of unbound antibody.
Thereafter, i.e., at a time the majority of unbound antibody will
have left the circulation, the abdominal skin was painted with
DNFB and mice received an intravenous injection of 51Cr-labeled
draining lymph node cells from DNFB sensitized mice. Circulation
and homing of the injected lymphocytes was followed for 48 h.
The majority of lymphocytes had left the circulation after 48 h
(Fig 6A). Yet, retention in the circulation was slightly increased
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Table IV. Anti-CD44 isoform specific antibodies differentially interfere with leukocyte sensitization and effector functions
Antibody Sensitization 1 challenge Sensitization Challenge
Influence of anti-CD44 on leukocyte expansion in the draining lymph node
No. (3106) of draining lymph node cellsa (p values) in dependence on antibody application timeb
Control IgG 14.0 6 2.1 14.2 6 1.3 13.9 6 1.1
Anti-CD44s 8.1 6 0.7 (0.014) 9.4 6 0.9 (,0.001) 13.5 6 1.2 (ns)
Anti-CD44v3 26.9 6 2.8 (,0.001) 18.9 6 1.5 (0.001) 14.3 6 0.9 (ns)
Anti-CD44v10 7.5 6 0.9 (,0.001) 8.8 6 1.5 (,0.001) 11.3 6 1.1 (0.011)
Influence of anti-CD44 on edema formation ears: mean diameter towards the roota (mm) (p values) in dependence on antibody application timeb
Control IgG 3.00 6 0.28 3.00 6 0.25 3.05 6 0.27
Anti-CD44s 1.20 6 0.11 (,0.001) 1.55 6 0.12 (,0.001) 1.50 6 0.18 (, 0.001)
Anti-CD44v3 1.15 6 0.13 (,0.001) 1.22 6 0.11 (,0.001) 1.15 6 0.16 (, 0.001)
Anti-CD44v10 1.02 6 0.12 (,0.001) 1.19 6 0.12 (,0.001) 1.02 6 0.18 (, 0.001)
Influence of anti-CD44 on leukocyte extravasation
No. (3105) of infiltrated cellsa (p values) in dependence on antibody application timeb
Control IgG 9.9 6 0.71 10.2 6 0.77 10.4 6 0.68
Anti-CD44s 5.5 6 0.49 (,0.001) 5.9 6 0.54 (,0.001) 5.0 6 0.60 (, 0.001)
Anti-CD44v3 4.0 6 0.46 (,0.001) 4.1 6 0.46 (,0.001) 4.0 6 0.42 (, 0.001)
Anti-CD44v10 2.5 6 0.49 (,0.001) 7.0 6 0.63 (,0.001) 6.0 6 0.76 (, 0.001)
aExpansion of draining lymph node cells, edema formation and the numbers of infiltrated cells were determined 48 h after challenge, mean 6 SD of five mice per group
are shown; ns, not significant.
bMice were sensitized and challenged with DNFB and received either concomitantly with the first sensitization or at the time of challenge or at both times an intravenous
injection of 200 µg antibody.
Figure 6. Blockade of CD44v3 on endothelial
cells interferes with leukocyte extravasation.
DNFB sensitized BALB/C mice were lethally
irradiated and received an intravenous injection
of control IgG or anti-CD44v3 or anti-CD44v10.
Forty-eight hours later they were reconstituted
with 51Cr-labeled draining lymph node cells from
DNFB-sensitized mice and the abdominal skin
was painted with DNFB. Distribution of the
injected lymphocytes was followed for 48 h. (A)
The recovery of lymphocytes in the peripheral
blood, bone marrow, spleen, and skin has been
evaluated by excision of the organs, weighing and
counting in a γ counter. The mean number of
counts per g tissue (6 SD) are shown. Significance
of differences are indicated by asterisks (*p , 0.1,
**p , 0.01, ***p , 0.001). Values were derived
from five mice per group. (B) Hematoxylin–
eosin-stained frozen sections of the painted skin
of sensitized, lethally irradiated, and reconstituted
mice (48 h after reconstitution), which received
after irradiation and 48 h before reconstitution
either a control IgG (a), anti-CD44v10 (b), or
anti-CD44v3 (c). The number of infiltrated cells
is strongly reduced in anti-CD44v10-treated mice.
In anti-CD44v3-treated mice hardly any infiltrat-
ing leukocytes could be detected. The experiment
was repeated two times (and three times with
antibody application 24 h before reconstitution).
All repetitions showed comparable results.
in anti-CD44v3-treated and anti-CD44v10-treated animals.
Degradation of lymphocytes as revealed by recovery of 51Cr from
the liver, the lung, and the kidney was independent of the antibody
treatment (data not shown). Notably, in control IgG-treated
mice and, although with delay, in anti-CD44v10-treated mice,
transferred cells were recovered in the painted area of the skin. In
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Figure 7. Influence of anti-CD44v3 and anti-
CD44v10 on cytokine expression and secretion
in a DNFB-induced DTH reaction. DTH was
induced as described above and leukocytes from the
draining lymph node (A, C) and the infiltrate (B,
D) were isolated 48 h after challenge. Cells were
stained with anti-IL-2, anti-IFN-γ, anti-TNF-α,
and anti-IL-12 (A, B). (C, D) Cells were pooled
from five mice and were seeded (1 3 104 cells per
well) in triplicates on plates coated with anti-IL-2,
anti-IFN-γ, anti-TNF-α, and anti-IL-12. Cells were
cultured for 24 h in the presence of DNP-OVA to
allow for cytokine secretion. After lysis of the cells,
cytokine secreting cells were visualized by staining
with detector antibodies. After 4 h at 37°C for
development of the substrate, individual spots were
counted. The mean (1SD) percentage of stained
leukocytes (A, B) and the mean number of stained
cells (C, D) are shown. Values were derived from
10 individually tested mice per group (A, B) or
from three individually tested pools (each consisting
of five mice) per group (C, D). Significance of
differences are indicated by asterisks (*p , 0.1,
**p , 0.01, ***p , 0.001).
anti-CD44v3-treated animals, hardly any leukocytes immigrated
into the painted skin (Fig 6A, B). Yet, a significantly increased
proportion of cells was retained in the draining lymph node
(Fig 6A).
We have shown above that anti-CD44v3 inhibits most strongly
the extravasation of CD81 cells, which by themselves do not
express CD44v3. Thus, the strongly reduced egress of leukocytes
in anti-CD44v3-treated mice cannot rely only on an alteration of
leukocyte migration, but is quite impressively influenced by the
occupancy of CD44v3 on endothelial cells of the dermis.
Influence of anti-CD44v3 and anti-CD44v10 on cytokine
production and secretion in a DTH reaction As stated above
the distinct influence of anti-CD44s, anti-CD44v3, and anti-
CD44v10 on leukocyte expansion has been suggestive for an
involvement of the anti-CD44 antibodies not only in leukocyte
migration, but also in leukocyte activation. As DNFB induces a
TH1 reaction, the hypothesis was tested by characterizing IL-2 and
IFN-γ as well as IL-12 and TNF-α expression, the latter two as
representatives of proinflammatory cytokines in TH1 reactions.
Cytokine expression was evaluated by flow cytometry, cytokine
secretion by the enzyme-linked immunosorbent spot assay.
All three anti-CD44 antibodies led to a small reduction of IL-2
and a strong reduction of IFN-γ expression in the draining lymph
node, anti-CD44v3 being the least effective. A strong reduction
in the expression of the proinflammatory cytokines TNF-α and
IL-12 was seen only in anti-CD44v10-treated mice (Fig 7A).
Cytokine secretion (Fig 7C) roughly corresponded to the pattern
of cytokine expression.
A comparison of cytokine expression on cells in the infiltrate
versus cells in the draining lymph node should provide an additional
hint as to the influence of anti-CD44 on lymphocyte activation
versus migration. Anti-CD44v10 inhibited cytokine expression and
secretion in the infiltrate in a similar way as in the draining lymph
node. Instead, in anti-CD44s-treated mice IL-2 expression and
secretion by infiltrated cells was hardly reduced. Whether this
phenomenon relates to the preferential blockade of monocyte
extravasation by anti-CD44s will be discussed. In anti-CD44v3-
treated mice, on the other hand, the reduction in the number of
cytokine expressing and secreting cells was much stronger in the
infiltrate than in the draining lymph node (Fig 7B, D). The latter
observation is in line with the above-mentioned interpretation that
anti-CD44v3 hampers the egress of activated leukocytes.
In summary, anti-CD44s exerted the strongest effect on cells
expressing the inflammatory cytokines IL-2 and IFN-γ, anti-
CD44v10 more strongly suppressed expression of the proinflam-
matory cytokines, whereas anti-CD44v3 efficiently inhibited IL-
12 and IFN-γ expression. Taking additionally into account that
CD44v10 is preferentially expressed on B cells and monocytes,
whereas CD44v3 is expressed on CD41 cells, B cells, and mono-
cytes, it was tempting to speculate that anti-CD44v3 and anti-
CD44v10 may interfere with the activation of APC rather than of
T cells.
Influence of anti-CD44v3 and anti-CD44v10 on cytokine
expression by leukocyte subsets To answer the question
whether anti-CD44v3 and anti-CD44v10 indeed block the activa-
tion of APC, their influence on cytokine expression by enriched
subpopulations of leukocytes was tested. Mice were sensitized with
DNFB. Draining lymph node cells were collected and were
enriched for leukocyte subsets as described in Materials and Methods.
Cells were cultured for 48 h in medium containing DNP-OVA
and T cell growth factor, the latter being used as an unspecific
growth stimulus plus either control IgG or anti-CD44v3 or anti-
CD44v10. Cytokine expression (IL-2, IL-12, IFN-γ, and TNF-α)
was evaluated by flow cytometry (Fig 8).
Anti-CD44v10, indeed, interfered strongly with IL-12, IFN-γ,
and TNF-α expression by monocytes, exerting only marginal
effects on CD41 and CD81 cells as well as B cells. Anti-
CD44v3 hardly affected cytokine expression by isolated leukocyte
subpopulations, solely IFN-γ expression by CD81 cells and mono-
cytes and IL-12 expression by CD41 cells and B cells has been
slightly reduced. As the effect of anti-CD44v3 appeared much
weaker in the isolated subpopulations than in unseparated leukocytes
recovered after in vivo sensitization, a second experiment was
performed where T cells were cocultured with irradiated B cells
or with monocytes. In the latter case only the nonadherent cells
were collected for flow cytometry (Fig 8B). The effect of anti-
CD44v10 on CD41 cells cocultured with irradiated B cells or with
monocytes roughly resembled the one on the separated CD41 cells.
Anti-CD44v3, however, strongly suppressed cytokine expression by
CD41 cells when cocultured with irradiated B cells or with
monocytes.
These data confirm that the major target of anti-CD44v10 are
monocytes. The effect of anti-CD44v3 on TH cells cultured in the
presence of APC indicates that CD44v3 is not only required for
leukocyte extravasation but also for a TH–APC interaction, which
initiates cytokine production by TH cells. In line with the finding
was the observation of a striking downregulation of CD40, CD80,
and CD86 on monocytes cultured in the presence of anti-CD44v3
(data not shown).
DISCUSSION
CD44 isoforms like many adhesion molecules are not only involved
in leukocyte adhesion and homing, but take actively part in
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Figure 8. CD44v3 and CD44v10 specific anti-
bodies influence cytokine production by dis-
tinct subpopulations of leukocytes. Mice were
sensitized with DNFB and were killed after 6 d.
PEC were collected and draining lymph node cells
were excised. Subpopulations of leukocytes were
separated as described in Materials and Methods and
were cultured in the presence of DNP-OVA, T cell
growth factor as an unspecific growth stimulus and
control IgG or anti-CD44. As far as CD41 cells
have been cocultured with B cells, the latter have
been irradiated; in cocultures of CD41 cells with
monocytes, only the nonadherent cells were col-
lected to assess solely cytokine expression by CD41
cells. Cells were collected after 48 h and were
stained with anti-IL-2, anti-IFN-γ, anti-TNF-α,
and anti-IL-12. The mean percentage (1SD) of
stained cells in three independently performed
experiments is shown. Significance of differences
are indicated by asterisks (*p , 0.1, **p , 0.01,
***p , 0.001).
leukocyte activation and regulation of response. This has been
known for several years for CD44s (Shimizu et al, 1989; Pierres
et al, 1992; Galandrini et al, 1993; Naujokas et al, 1993; Funaro
et al, 1994) and has been suggested for some of the variant isoforms,
particularly CD44v6, but also for CD44v3 and recently for CD44v7
and CD44v10 (Arch et al, 1992; Koopman et al, 1993; Bennett
et al, 1995; Galluzzo et al, 1995; Jackson et al, 1995; Levesque et al,
1996; Weiss et al, 1997; Ro¨sel et al, 1998; Wittig et al, 1998). Here
we demonstrate in a model system the involvement of distinct
CD44 isoforms in a pathologic DTH reaction. Furthermore,
we provide evidence that CD44v3 and CD44v10 exert distinct
functional activities. CD44v10 functions predominantly as a recep-
tor molecule on monocytes, whereas CD44v3 functions as a ligand
on APC for an as yet undefined costimulatory molecule on CD41
cells. In addition, expression of CD44v3 on endothelial cells is of
particular importance for leukocyte extravasation.
Ear swelling, but most pronounced, infiltration of lymphocytes
in DNFB-induced DTH reactions was impaired when mice were
treated with anti-CD44s, anti-CD44v3, or anti-CD44v10, but a
state of tolerance could not be induced, i.e., upon re-challenge
an unimpaired DTH reaction was observed (data not shown).
Interestingly, the inhibitory effect of the three antibodies was
comparably strong. This finding was puzzling, because CD44
variant isoforms are expressed at a very low level and on small
subpopulations of cells, whereas CD44s is strongly expressed on
the majority of lymphocytes and expression is further upregulated
during the activation process. As a possible explanation we took
into consideration that the antibody blockade may not have
functioned exclusively on the level of leukocytes. To support our
hypothesis, we first evaluated the influence of anti-CD44 antibodies
on leukocyte activation, which included the analysis of expression
and secretion of IL-2 and IFN-γ as prototype TH1 cytokines
(Shanley et al, 1995) and of IL-12 and TNF-α as prototype TH1
proinflammatory cytokines (Trinchieri, 1995), the latter being
known to be of critical importance for provoking clinical manifesta-
tions after exposure to contact allergens (Grabbe and Schwarz,
1996). Second, we examined whether CD44 isoform-specific
antibodies interfere with leukocyte extravasation and whether such
an interference is due to a blockade of activated leukocytes or
activated endothelial cells.
In the described model of a DNFB-induced DTH reaction,
treatment with anti-CD44s affected both leukocyte activation
and the elucidation phase with edema formation and leukocyte
infiltration. Accordingly, the DTH reaction was mitigated, although
to a lesser degree, when the antibody was given either during the
sensitization or the exacerbation period. With respect to lymphocyte
activation, anti-CD44s most strongly affected expression of IL-2
and IFN-γ. The finding could well be explained by a blockade of
TH1 activation. Yet, it remains to be explored whether this results
from a blockade of CD44s functioning as a ligand or as a
costimulatory molecule, both features have been ascribed to CD44s:
Cross-linking of CD44s on T cells provides a costimulatory signal
(Gruber et al, 1992; Pierres et al, 1992). A CD40–CD40L interaction
initiates a rapid upregulation of CD44 on APC, which by binding
to a so far unknown ligand on T cells provides a strong stimulus
for proliferation (Guo et al, 1996).
DeGrendele et al (1997) have described that blockade of the
CD44s isoform interferes not only with lymphocyte activation but
also with leukocyte emigration, particularly of monocytes. Our
study and reports by other groups (Camp et al, 1993; Weiss et al,
1997) confirm this inasmuch as anti-CD44s inhibited edema
formation and leukocyte infiltration even when applied only during
the effector phase.
If anti-CD44s functions during sensitization and elucidation,
how do we explain that anti-CD44s had less effect on IL-2
expression in infiltrated cells than in draining lymph node cells? In
line with the study by deGrendele et al (1997), we noted that in
anti-CD44s-treated mice the percentage of monocytes in the
infiltrate was significantly reduced. Therefore we suggest that,
although fewer T cells will become activated in the presence of
anti-CD44s, the egress of T cells may not be influenced significantly
and, as a consequence, the percentage of activated, IL-2 expressing
T cells in the infiltrate will not be significantly reduced in anti-
CD44s-treated mice.
Thus, in the TH1-mediated DTH model anti-CD44s blocked T
cell activation and, preferentially, monocyte extravasation. Notably,
there has been no evidence for a linkage of the two processes.
Anti-CD44v10, too, has been shown to interfere strongly with
TH1-mediated DTH reactions (Ro¨sel et al, 1997). The presented
data extend this earlier study inasmuch as they demonstrate that
anti-CD44v10 suppressed most strongly TNF-α, IL-12, and IFN-γ
expression and secretion. The analysis of cytokine expression by
subpopulations of leukocytes revealed that the blockade of cytokine
production by anti-CD44v10 was clearly restricted to APC. Fur-
thermore, in anti-CD44v10-treated, like in anti-CD44s-treated
mice, the infiltrate contained a significantly reduced percentage of
monocytes. Different to anti-CD44s, cytokine expression was
blocked in the draining lymph node as well as in the infiltrate of
anti-CD44v10-treated animals. We interpret these findings in
the sense that anti-CD44v10 directly inhibits the activation of
monocytes in the draining lymph node, where they may function
as APC as well as in the infiltrate during the elucidation phase of
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the response. Considering the latter aspect, we want to mention
that anti-CD44 has been described to interfere with TNF release
(Zembala et al, 1994) and to block nitric oxide release by activated
monocytes (DelPozo et al, 1995). Although these studies were not
concerned about distinct CD44 isoforms, according to our study
it is tempting to speculate, although not yet proved, that CD44v10
has been involved. Irrespective of this open question, we clearly
could demonstrate that mitigation of a DTH reaction by anti-
CD44v10 proceeds quite exclusively via a blockade of the mono-
cytes. It may be added that sensitization with DNFB induces a
rather severe DTH reaction with fever and weight loss. As compared
with anti-CD44s and anti-CD44v3, anti-CD44v10 had the
strongest effect on improving the overall physical conditions of the
DNFB-treated mice.
Anti-CD44s and anti-CD44v10 are known to mitigate a DTH
reaction and have been included in the study as ‘‘positive controls’’,
but also to explore whether they block alike or distinct activities
of elements of the immune system. Yet, the prime object of our
study was the definition of possible functions of CD44v3. The
interest in CD44v3 derived from the observation that dermal
infiltrates of patients with autoimmune and allergic skin reactions
contain CD44v31 cells, but neither CD44v61 nor CD44v71, and
rarely CD44v101 cells (Seiter et al, 1998). Furthermore, in humans
and mice, vessel endothelium of the dermis can be CD44v31.
The most striking effects of anti-CD44v3 were (i) a strongly
reduced number of infiltrated cells, and (ii) an overshooting
expansion of draining lymph node cells. We have no explanation
for the latter phenomenon. Yet, it should be mentioned that the
molecule has been described to function as receptor for basic
fibroblast growth factor and for heparin-binding growth factor
(Bennett et al, 1995; Jackson et al, 1995) and possibly for MIP-1β
(Tanaka et al, 1993). Furthermore, although the influence of anti-
CD44v3 on cytokine production by leukocyte subpopulations was
minor, the antibody strongly interfered with cytokine production
by CD41 cells cultured together with irradiated B cells or mono-
cytes. Thus, CD44v3 does not only function as a receptor for
cytokines, but CD44v3–CD44v3 ligand binding plays an essential
part in triggering cytokine production by CD41 cells. Whether
this in turn supports clonal expansion of T cells remains to be
explored. We are currently establishing a CD44v3 receptor globulin
to identify the ligand for CD44v3 and to elucidate by which
mechanism CD44v3–CD44v3 ligand interaction initiates cytokine
production.
Considering the strongly reduced number of cells in the infiltrate
of anti-CD44v3-treated mice, the fact that activated vessel endo-
thelium strongly expressed CD44v3 has to be taken into account.
Thus, and despite the fact that anti-CD44v3 exerted some effect
on leukocyte activation/cytokine expression, we presume that anti-
CD44v3 interfered with the DTH reaction predominantly by a
blockade of leukocyte extravasation. In line with this interpretation
are the findings that (i) application of anti-CD44v3 during the
effector phase sufficed for a strongly impaired extravasation of
leukocytes, and that (ii) extravasation of leukocytes could not be
detected in the anti-CD44v3 pretreated, lethally irradiated and
reconstituted host. According to the latter aspect it could well be
that mitigation of a DTH reaction by anti-CD44v3 is, at least
partly, due to the blockade of CD44v3 rather on endothelial cells
than on leukocytes. The finding that anti-CD44v3 inhibits most
strongly the egress of CD81 cells, which rarely are CD44v31,
strengthens our interpretation.
In conclusion, CD44s, CD44v3, and CD44v10 isoform-specific
antibodies interfere with TH1-mediated DTH reactions. The seem-
ingly similar effect is based on different functional activities. Anti-
CD44s interferes with T cell activation and with the egress
preferentially of monocytes. Anti-CD44v10 predominantly pre-
vents the activation of monocytes. Anti-CD44v3 hampers an
interaction between APC and CD41 T cells with the consequence
of an impaired TH cell activation. Yet, the dominating effect of
anti-CD44v3 is the strong inhibition of the extravasation of
activated leukocytes, which likely includes a blockade of CD44v3
on the vessel endothelium. Knowledge of these distinct activities
will be important for any consideration of therapeutic interference.
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